Cargando…
Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
Cardiovascular disease (CVD) constitutes a real pandemic of the 21st century. According to data from the Centers for Disease Control and Prevention, one person dies every 34 min due to some form of CVD in the United States. Apart from the extremely high morbidity and mortality accompanying CVD, the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962740/ https://www.ncbi.nlm.nih.gov/pubmed/36835838 http://dx.doi.org/10.3390/jcm12041302 |
_version_ | 1784896080725409792 |
---|---|
author | Dimosiari, Athina Patoulias, Dimitrios Kitas, George D. Dimitroulas, Theodoros |
author_facet | Dimosiari, Athina Patoulias, Dimitrios Kitas, George D. Dimitroulas, Theodoros |
author_sort | Dimosiari, Athina |
collection | PubMed |
description | Cardiovascular disease (CVD) constitutes a real pandemic of the 21st century. According to data from the Centers for Disease Control and Prevention, one person dies every 34 min due to some form of CVD in the United States. Apart from the extremely high morbidity and mortality accompanying CVD, the economic burden seems to be unbearable even for developed countries in the Western World. The role of inflammation in the development and progression of CVD appears to be crucial, while, various inflammatory pathways, such as the Nod-like receptor protein 3 (NLRP3) inflammasome-interleukin (IL)-1/IL-6 pathway of the innate immunity, have attracted scientific interest during the last decade, as a potential treatment target in primary and/or secondary prevention of CVD. Whereas there is a significant amount of evidence, stemming mainly from observational studies, concerning the cardiovascular safety of IL-1 and IL-6 antagonists in patients with rheumatic diseases, evidence from relevant randomized controlled trials (RCTs) is rather scarce and conflicting, especially for patients without underlying rheumatic disease. In this review, we summarize and critically present the currently available evidence, both from RCTs and observational studies, concerning the place that IL-1 and IL-6 antagonists may hold in the treatment of CVD. |
format | Online Article Text |
id | pubmed-9962740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99627402023-02-26 Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence Dimosiari, Athina Patoulias, Dimitrios Kitas, George D. Dimitroulas, Theodoros J Clin Med Review Cardiovascular disease (CVD) constitutes a real pandemic of the 21st century. According to data from the Centers for Disease Control and Prevention, one person dies every 34 min due to some form of CVD in the United States. Apart from the extremely high morbidity and mortality accompanying CVD, the economic burden seems to be unbearable even for developed countries in the Western World. The role of inflammation in the development and progression of CVD appears to be crucial, while, various inflammatory pathways, such as the Nod-like receptor protein 3 (NLRP3) inflammasome-interleukin (IL)-1/IL-6 pathway of the innate immunity, have attracted scientific interest during the last decade, as a potential treatment target in primary and/or secondary prevention of CVD. Whereas there is a significant amount of evidence, stemming mainly from observational studies, concerning the cardiovascular safety of IL-1 and IL-6 antagonists in patients with rheumatic diseases, evidence from relevant randomized controlled trials (RCTs) is rather scarce and conflicting, especially for patients without underlying rheumatic disease. In this review, we summarize and critically present the currently available evidence, both from RCTs and observational studies, concerning the place that IL-1 and IL-6 antagonists may hold in the treatment of CVD. MDPI 2023-02-06 /pmc/articles/PMC9962740/ /pubmed/36835838 http://dx.doi.org/10.3390/jcm12041302 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Dimosiari, Athina Patoulias, Dimitrios Kitas, George D. Dimitroulas, Theodoros Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence |
title | Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence |
title_full | Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence |
title_fullStr | Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence |
title_full_unstemmed | Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence |
title_short | Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence |
title_sort | do interleukin-1 and interleukin-6 antagonists hold any place in the treatment of atherosclerotic cardiovascular disease and related co-morbidities? an overview of available clinical evidence |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962740/ https://www.ncbi.nlm.nih.gov/pubmed/36835838 http://dx.doi.org/10.3390/jcm12041302 |
work_keys_str_mv | AT dimosiariathina dointerleukin1andinterleukin6antagonistsholdanyplaceinthetreatmentofatheroscleroticcardiovasculardiseaseandrelatedcomorbiditiesanoverviewofavailableclinicalevidence AT patouliasdimitrios dointerleukin1andinterleukin6antagonistsholdanyplaceinthetreatmentofatheroscleroticcardiovasculardiseaseandrelatedcomorbiditiesanoverviewofavailableclinicalevidence AT kitasgeorged dointerleukin1andinterleukin6antagonistsholdanyplaceinthetreatmentofatheroscleroticcardiovasculardiseaseandrelatedcomorbiditiesanoverviewofavailableclinicalevidence AT dimitroulastheodoros dointerleukin1andinterleukin6antagonistsholdanyplaceinthetreatmentofatheroscleroticcardiovasculardiseaseandrelatedcomorbiditiesanoverviewofavailableclinicalevidence |